Collegium Pharmaceutical, Inc. (COLL) Stock Analysis

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis — AI Research | MarketCI

COLL

Market Closed

Collegium Pharmaceutical, Inc.

NASDAQHealthcare Drug Manufacturers - Specialty & Generic

423 employees

CEO: Vikram Karnani

Founded: 2015

$35.20

+$0.00(+NaN%)

Market Cap

1.14B

Beta

0.73

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

COLL Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for COLL built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Hold

Pass %

57.14%

Score

4/7

Fair Value Estimate

Cash flow analysis • Multiple methods

$640.86

AI Price Target

Machine learning • Price prediction

$34.69

Market Sentiment

News & social media analysis

0.00

Value Investor Price

Classic value analysis

$9.95

Financial Health

Bankruptcy risk assessment

1.67

Quality Score

Financial strength rating

7.00

AI Investment Grade

Deep analysis of filings & news

75.00

Key Investment Highlights

Important factors affecting COLL investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

64.10% Good

Conditions Met

25.00/39.00

Due Diligence Score

64.10%

Due Diligence Conditions

Investment analysis conditions and results


	Pass
	Pass
	Pass
	Pass
	Pass
	Pass

Showing 1 to 6 of 46 conditions